Technology | April 09, 2026
Halozyme strikes global deal with Vertex to expand Hypercon drug delivery technology
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The results were consistent across both the 10 mg and 40 mg treatment arms
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Subscribe To Our Newsletter & Stay Updated
